An immunomodulator enhances T cell activity post-radiotherapy, suggesting improved cancer treatment outcomes.
T cell exhaustion within the tumor immune microenvironment (TIME) impairs the efficacy of radioimmunotherapy. Here, we demonstrate that X-ray radiotherapy induces arginine metabolic dysregulation and PD-L1 upregulation in the tumor microenvironment (TME), suppressing T cell metabolism and driving the expansion of PD-1+TIM-3+ exhausted T cells, thereby promoting immunosuppression. To address this, we design a biomimetic hybrid immunomodulator (arg/Bnb-L) by engineering BL-21 bacterial membranes to display PD-L1 nanobodies and fusing them with l-arginine-loaded liposomes. This nanoplatform simultaneously blocks PD-1/PD-L1 immune checkpoint signaling and restores T cell metabolic activity while promoting dendritic cell maturation. In murine tumor models, arg/Bnb-L combined with radiotherapy significantly enhances CD8+ T cell infiltration, reduces exhausted T cell populations, maintains cytotoxic T lymphocyte function, and inhibits tumor progression and metastasis. Our study elucidates a dual mechanism underlying radiotherapy-induced immunosuppression and offers a promising strategy to enhance radioimmunotherapy outcomes through targeted metabolic and immunologic reprogramming.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: